数据凸显了ZL-1503有望成为中重度特应性皮炎及其他IL-13/IL-31驱动疾病疗法的潜力优异的临床前安全性特征、延长的半衰期特性及对炎症和致痒通路的持续抑制,为ZL-1503推进至临床试验申报支持性研究阶段提供了支持再鼎医药计划于2025年底前提交ZL-1503治疗中重度特应性皮炎的临床试验申请中国上海和美国马萨诸塞州剑桥,2025年6月13日——再鼎医药(纳斯达克股票代码:ZLAB;...
Source Link数据凸显了ZL-1503有望成为中重度特应性皮炎及其他IL-13/IL-31驱动疾病疗法的潜力优异的临床前安全性特征、延长的半衰期特性及对炎症和致痒通路的持续抑制,为ZL-1503推进至临床试验申报支持性研究阶段提供了支持再鼎医药计划于2025年底前提交ZL-1503治疗中重度特应性皮炎的临床试验申请中国上海和美国马萨诸塞州剑桥,2025年6月13日——再鼎医药(纳斯达克股票代码:ZLAB;...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.